human srage Search Results


92
Krishgen Biosystems human srage
Human Srage, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human srage/product/Krishgen Biosystems
Average 92 stars, based on 1 article reviews
human srage - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

90
OriGene rage expression vector
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Rage Expression Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rage expression vector/product/OriGene
Average 90 stars, based on 1 article reviews
rage expression vector - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
OriGene expression vector pcmv6 entry
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Expression Vector Pcmv6 Entry, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/expression vector pcmv6 entry/product/OriGene
Average 90 stars, based on 1 article reviews
expression vector pcmv6 entry - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

91
BioVendor Instruments elisa kit
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Elisa Kit, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/BioVendor Instruments
Average 91 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

91
OriGene rage nm 001136
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Rage Nm 001136, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rage nm 001136/product/OriGene
Average 91 stars, based on 1 article reviews
rage nm 001136 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

90
Cyclex Inc human srage elisa kit
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Human Srage Elisa Kit, supplied by Cyclex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human srage elisa kit/product/Cyclex Inc
Average 90 stars, based on 1 article reviews
human srage elisa kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Novartis human srage
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Human Srage, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human srage/product/Novartis
Average 90 stars, based on 1 article reviews
human srage - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Shanghai Coon Koon Biotech Co Ltd human soluble receptor for advanced glycation end products (srage) elisa kit
Involvement of the coupled <t>RAGE</t> ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells <t>transiently</t> <t>transfected</t> with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.
Human Soluble Receptor For Advanced Glycation End Products (Srage) Elisa Kit, supplied by Shanghai Coon Koon Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human soluble receptor for advanced glycation end products (srage) elisa kit/product/Shanghai Coon Koon Biotech Co Ltd
Average 90 stars, based on 1 article reviews
human soluble receptor for advanced glycation end products (srage) elisa kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Aviscera Bioscience Inc human soluble receptor for advanced glycosylation end products (srage) elisa kit
Generation and characterization of <t>sRAGE</t> secreting UCB-MSC. (A) The illustration picture represents the gene information of pZDonor-AAVS1 puromycin vector. Each arrow describes certain gene. (B) The illustration of the sRAGE insertion coding sequence. (C) Genome integration was confirmed by Junction PCR with genomic DNAs of UCB-MSCs which were transfected with mock, GFP and sRAGE containing pZDonor-AAVS1 plasmids. (D) Immunoblot analysis of supernatant and extract from UCB-MSC cells transfected with mock (lane 1) and FLAG-tagged sRAGE in pZDonor-AAVS1 vector (lane 2). β -actin loaded as a positive control. The secretion of human sRAGE levels (E) was confirmed with <t>ELISA.</t> ***p<0.001.
Human Soluble Receptor For Advanced Glycosylation End Products (Srage) Elisa Kit, supplied by Aviscera Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human soluble receptor for advanced glycosylation end products (srage) elisa kit/product/Aviscera Bioscience Inc
Average 90 stars, based on 1 article reviews
human soluble receptor for advanced glycosylation end products (srage) elisa kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Novoprotein recombinant human srage
Generation and characterization of <t>sRAGE</t> secreting UCB-MSC. (A) The illustration picture represents the gene information of pZDonor-AAVS1 puromycin vector. Each arrow describes certain gene. (B) The illustration of the sRAGE insertion coding sequence. (C) Genome integration was confirmed by Junction PCR with genomic DNAs of UCB-MSCs which were transfected with mock, GFP and sRAGE containing pZDonor-AAVS1 plasmids. (D) Immunoblot analysis of supernatant and extract from UCB-MSC cells transfected with mock (lane 1) and FLAG-tagged sRAGE in pZDonor-AAVS1 vector (lane 2). β -actin loaded as a positive control. The secretion of human sRAGE levels (E) was confirmed with <t>ELISA.</t> ***p<0.001.
Recombinant Human Srage, supplied by Novoprotein, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human srage/product/Novoprotein
Average 90 stars, based on 1 article reviews
recombinant human srage - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
MyBiosource Biotechnology elisa kit for the srage human receptor
( A ) Graph of the correlation between the level of glycated hemoglobin HbA1c and the concentration of the SR-AI <t>scavenger</t> <t>receptor</t> in the samples. ( B ) Graph of the correlation between the level of glycated hemoglobin HbA1c and fluorescence of soluble pentosidine. ( C ) Graph of the correlation between the concentration of HDL and AGEs content in samples digested with proteinase K (the competitive <t>ELISA</t> test). Graph of the correlation between the levels of GFR. ( D ) and creatinine. ( E ) and the concentration of the SR-AI receptor in the serum samples. ( F ) Graph of the correlation between the level of uric acid and the fluorescence value of protein-bound total AGEs in the serum samples.
Elisa Kit For The Srage Human Receptor, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit for the srage human receptor/product/MyBiosource Biotechnology
Average 90 stars, based on 1 article reviews
elisa kit for the srage human receptor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
ZellBio GmbH human srage elisa kit
( A ) Graph of the correlation between the level of glycated hemoglobin HbA1c and the concentration of the SR-AI <t>scavenger</t> <t>receptor</t> in the samples. ( B ) Graph of the correlation between the level of glycated hemoglobin HbA1c and fluorescence of soluble pentosidine. ( C ) Graph of the correlation between the concentration of HDL and AGEs content in samples digested with proteinase K (the competitive <t>ELISA</t> test). Graph of the correlation between the levels of GFR. ( D ) and creatinine. ( E ) and the concentration of the SR-AI receptor in the serum samples. ( F ) Graph of the correlation between the level of uric acid and the fluorescence value of protein-bound total AGEs in the serum samples.
Human Srage Elisa Kit, supplied by ZellBio GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human srage elisa kit/product/ZellBio GmbH
Average 90 stars, based on 1 article reviews
human srage elisa kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Involvement of the coupled RAGE ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells transiently transfected with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.

Journal: Investigative Ophthalmology & Visual Science

Article Title: Advanced Glycation End Products and Receptor (RAGE) Promote Wound Healing of Human Corneal Epithelial Cells

doi: 10.1167/iovs.61.3.14

Figure Lengend Snippet: Involvement of the coupled RAGE ligand/receptor in human corneal epithelial (HCE) cell wound healing. Representative images of scratch assays performed on HCE cells (left panel) treated with HMGB1 (high mobility group box 1, 100 ng/mL) ( A ) or AGEs (advanced glycation end products) (10/100/200 µg/mL) (B , C ). Percentage of residual wound area (right panel) after treatment with HMGB1 (100 ng/mL) ( A ) or AGEs (10/100/200 µg/mL) ( B , C ), compared with 0 hours and standardized to the untreated condition (100%) (n = 5 experiments, each conducted in duplicate). ( D ) Representative images of scratch assays performed on HCE cells transiently transfected with siRNA against RAGE (siRNA RAGE) or siRNA control (Scramble) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) (left panel). Percentage of the residual wound area of HCE cells transfected with siRNA against RAGE (100 nM) for 36 hours and then treated with AGEs (100 µg/mL), compared with 0 h (right panel) (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney test after a nonparametric ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.005; ns: not significant.

Article Snippet: Cells were transfected with 1 µg RAGE expression vector (RG204664; Origene, Herford, Germany) in the presence of 125 µL opti-MEM 1× and 5 µL p3000 reagent, mixed with 3.75 µL Lipofectamine 3000 reagent in 125 µL of opti-MEM (1×).

Techniques: Transfection, MANN-WHITNEY

Functionality of the RAGE pathway. Characterization of the RAGE ( A ) mRNA and ( B ) protein expression in human cornea, primary human epithelial cells (mRNA only), and the HCE cell line (mRNA and protein) evaluated by ( A ) RT-PCR, ( B ) immunofluorescence, and ( B ) western blotting. For RT-PCR, negative controls (NC) were performed ( A ) without cDNA. ( B , left panel) Representative images of RAGE expression ( green ) in human corneas (top panel) and HCE cells (bottom panel). Nuclei were stained with Hoechst ( blue ); NC (left) were obtained by incubating HCE cells without primary antibody. ( B , right panel) Western blot experiments identified the RAGE protein at the described molecular weight (46 kDa). ( C ) Functionality of the NF-κB pathway (by luciferase reporter gene activity) was measured after treatment of HCE cells with AGEs (100 µg/mL) for 45 minutes (n = 5 experiments, each conducted in duplicate) (right panel). Positive controls (T+) were obtained by co-transfection with pMEKK (n = 5 experiments, each conducted in duplicate) (left panel). Each bar graph shows mean ± SEM. Mann-Whitney; * P < 0.05.

Journal: Investigative Ophthalmology & Visual Science

Article Title: Advanced Glycation End Products and Receptor (RAGE) Promote Wound Healing of Human Corneal Epithelial Cells

doi: 10.1167/iovs.61.3.14

Figure Lengend Snippet: Functionality of the RAGE pathway. Characterization of the RAGE ( A ) mRNA and ( B ) protein expression in human cornea, primary human epithelial cells (mRNA only), and the HCE cell line (mRNA and protein) evaluated by ( A ) RT-PCR, ( B ) immunofluorescence, and ( B ) western blotting. For RT-PCR, negative controls (NC) were performed ( A ) without cDNA. ( B , left panel) Representative images of RAGE expression ( green ) in human corneas (top panel) and HCE cells (bottom panel). Nuclei were stained with Hoechst ( blue ); NC (left) were obtained by incubating HCE cells without primary antibody. ( B , right panel) Western blot experiments identified the RAGE protein at the described molecular weight (46 kDa). ( C ) Functionality of the NF-κB pathway (by luciferase reporter gene activity) was measured after treatment of HCE cells with AGEs (100 µg/mL) for 45 minutes (n = 5 experiments, each conducted in duplicate) (right panel). Positive controls (T+) were obtained by co-transfection with pMEKK (n = 5 experiments, each conducted in duplicate) (left panel). Each bar graph shows mean ± SEM. Mann-Whitney; * P < 0.05.

Article Snippet: Cells were transfected with 1 µg RAGE expression vector (RG204664; Origene, Herford, Germany) in the presence of 125 µL opti-MEM 1× and 5 µL p3000 reagent, mixed with 3.75 µL Lipofectamine 3000 reagent in 125 µL of opti-MEM (1×).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Immunofluorescence, Western Blot, Staining, Molecular Weight, Luciferase, Activity Assay, Cotransfection, MANN-WHITNEY

Cx43 expression is induced by the AGEs/RAGE axis in HCE cells. Characterization of Cx43 protein expression ( arrow ) by immunostaining (bottom panel). Cells incubated without primary antibody served as a negative control (NC). ( B ) Relative quantification of Cx43 mRNA expression in untreated HCE cells 0, 6, and 24 hours after scratch wounding. Results were expressed as a ratio of the 0-hour condition (n = 5 experiments, each conducted in duplicate). ( C ) Quantification of Cx43 mRNA expression in HCE cells treated with AGEs (100 µg/mL) for 6 hours or 24 hours without scratch wounding (left panel) or with scratch wounding (right panel). Cells not treated with AGEs served as a control. Results were expressed as a ratio of the untreated condition at each time point (n = 5 experiments, each conducted in duplicate). (Left panel) Quantification of Cx43 mRNA expression in HCE cells transiently transfected with siRNA against RAGE (siRNA RAGE) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) for 6 hours. Results were expressed as a ratio of the scrambled siRNA condition (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney after a nonparametric ANOVA analysis; * P < 0.05; ns: not significant. ( D ) Relative quantification of Cx43 protein expression in HCE cells following treatment with AGEs (100 µg/mL) after scratch wounding. Untreated cells served as a control. Results were expressed as a ratio of the 0-hour, unwounded condition (n = 5 experiments) (top panel). Quantification of Cx43 protein expression in HCE cells treated with AGEs (100 µg/mL) for 12 and 24 hours after scratch wounding (bottom panel). Results were expressed as a ratio of the untreated condition at each time point (n = 5 experiments, each conducted in duplicate) (** P < 0.01). (E) Characterization by immunostaining of Cx43 protein expression according to the distance from the wound, time, and treatment with AGEs (100 µg/mL). Staining of Cx43 protein expression in HCE cells treated near the wound margins (left panel) and behind the wound (right panel). Cells not treated with AGEs (100 µg/mL) served as a control. Cells incubated without primary antibody served as a negative control (NC).

Journal: Investigative Ophthalmology & Visual Science

Article Title: Advanced Glycation End Products and Receptor (RAGE) Promote Wound Healing of Human Corneal Epithelial Cells

doi: 10.1167/iovs.61.3.14

Figure Lengend Snippet: Cx43 expression is induced by the AGEs/RAGE axis in HCE cells. Characterization of Cx43 protein expression ( arrow ) by immunostaining (bottom panel). Cells incubated without primary antibody served as a negative control (NC). ( B ) Relative quantification of Cx43 mRNA expression in untreated HCE cells 0, 6, and 24 hours after scratch wounding. Results were expressed as a ratio of the 0-hour condition (n = 5 experiments, each conducted in duplicate). ( C ) Quantification of Cx43 mRNA expression in HCE cells treated with AGEs (100 µg/mL) for 6 hours or 24 hours without scratch wounding (left panel) or with scratch wounding (right panel). Cells not treated with AGEs served as a control. Results were expressed as a ratio of the untreated condition at each time point (n = 5 experiments, each conducted in duplicate). (Left panel) Quantification of Cx43 mRNA expression in HCE cells transiently transfected with siRNA against RAGE (siRNA RAGE) (100 nM) for 36 hours and then treated with AGEs (100 µg/mL) for 6 hours. Results were expressed as a ratio of the scrambled siRNA condition (n = 5 experiments, each conducted in duplicate). Each bar graph shows mean ± SEM. Mann-Whitney after a nonparametric ANOVA analysis; * P < 0.05; ns: not significant. ( D ) Relative quantification of Cx43 protein expression in HCE cells following treatment with AGEs (100 µg/mL) after scratch wounding. Untreated cells served as a control. Results were expressed as a ratio of the 0-hour, unwounded condition (n = 5 experiments) (top panel). Quantification of Cx43 protein expression in HCE cells treated with AGEs (100 µg/mL) for 12 and 24 hours after scratch wounding (bottom panel). Results were expressed as a ratio of the untreated condition at each time point (n = 5 experiments, each conducted in duplicate) (** P < 0.01). (E) Characterization by immunostaining of Cx43 protein expression according to the distance from the wound, time, and treatment with AGEs (100 µg/mL). Staining of Cx43 protein expression in HCE cells treated near the wound margins (left panel) and behind the wound (right panel). Cells not treated with AGEs (100 µg/mL) served as a control. Cells incubated without primary antibody served as a negative control (NC).

Article Snippet: Cells were transfected with 1 µg RAGE expression vector (RG204664; Origene, Herford, Germany) in the presence of 125 µL opti-MEM 1× and 5 µL p3000 reagent, mixed with 3.75 µL Lipofectamine 3000 reagent in 125 µL of opti-MEM (1×).

Techniques: Expressing, Immunostaining, Incubation, Negative Control, Transfection, MANN-WHITNEY, Staining

Generation and characterization of sRAGE secreting UCB-MSC. (A) The illustration picture represents the gene information of pZDonor-AAVS1 puromycin vector. Each arrow describes certain gene. (B) The illustration of the sRAGE insertion coding sequence. (C) Genome integration was confirmed by Junction PCR with genomic DNAs of UCB-MSCs which were transfected with mock, GFP and sRAGE containing pZDonor-AAVS1 plasmids. (D) Immunoblot analysis of supernatant and extract from UCB-MSC cells transfected with mock (lane 1) and FLAG-tagged sRAGE in pZDonor-AAVS1 vector (lane 2). β -actin loaded as a positive control. The secretion of human sRAGE levels (E) was confirmed with ELISA. ***p<0.001.

Journal: International Journal of Stem Cells

Article Title: CRISPR/Cas9 Edited sRAGE-MSCs Protect Neuronal Death in Parkinson’s Disease Model

doi: 10.15283/ijsc18110

Figure Lengend Snippet: Generation and characterization of sRAGE secreting UCB-MSC. (A) The illustration picture represents the gene information of pZDonor-AAVS1 puromycin vector. Each arrow describes certain gene. (B) The illustration of the sRAGE insertion coding sequence. (C) Genome integration was confirmed by Junction PCR with genomic DNAs of UCB-MSCs which were transfected with mock, GFP and sRAGE containing pZDonor-AAVS1 plasmids. (D) Immunoblot analysis of supernatant and extract from UCB-MSC cells transfected with mock (lane 1) and FLAG-tagged sRAGE in pZDonor-AAVS1 vector (lane 2). β -actin loaded as a positive control. The secretion of human sRAGE levels (E) was confirmed with ELISA. ***p<0.001.

Article Snippet: Human soluble receptor for advanced glycosylation end products (sRAGE) ELISA kit (Aviscera Bioscience) was used to quantify the amount of secreted sRAGE.

Techniques: Plasmid Preparation, Sequencing, Transfection, Western Blot, Positive Control, Enzyme-linked Immunosorbent Assay

( A ) Graph of the correlation between the level of glycated hemoglobin HbA1c and the concentration of the SR-AI scavenger receptor in the samples. ( B ) Graph of the correlation between the level of glycated hemoglobin HbA1c and fluorescence of soluble pentosidine. ( C ) Graph of the correlation between the concentration of HDL and AGEs content in samples digested with proteinase K (the competitive ELISA test). Graph of the correlation between the levels of GFR. ( D ) and creatinine. ( E ) and the concentration of the SR-AI receptor in the serum samples. ( F ) Graph of the correlation between the level of uric acid and the fluorescence value of protein-bound total AGEs in the serum samples.

Journal: Scientific Reports

Article Title: Advanced glycation end products and their receptors in serum of patients with type 2 diabetes

doi: 10.1038/s41598-021-92630-0

Figure Lengend Snippet: ( A ) Graph of the correlation between the level of glycated hemoglobin HbA1c and the concentration of the SR-AI scavenger receptor in the samples. ( B ) Graph of the correlation between the level of glycated hemoglobin HbA1c and fluorescence of soluble pentosidine. ( C ) Graph of the correlation between the concentration of HDL and AGEs content in samples digested with proteinase K (the competitive ELISA test). Graph of the correlation between the levels of GFR. ( D ) and creatinine. ( E ) and the concentration of the SR-AI receptor in the serum samples. ( F ) Graph of the correlation between the level of uric acid and the fluorescence value of protein-bound total AGEs in the serum samples.

Article Snippet: sRAGE was determined using the ELISA kit for the sRAGE human receptor (MyBioSource, cat. no. MBS766075) according to the manufacturer's instructions.

Techniques: Concentration Assay, Fluorescence, Competitive ELISA

Graphs of the dependence of AGEs fluorescence or content of sRAGE in the samples and occurrence diabetic complications in patients. The numbers given are the mean value of the results and the standard error of the mean (Mean ± SE). ( A ) The dependence of total AGEs fluorescence on the type of diabetes; (number of subjects = 49; Type 1 (1,167,393 ± 70,632 a.u.), Type 2 (1,517,352 ± 98,785 a.u.)). ( B ) The dependence of total soluble AGEs fluorescence on the occurrence of atherosclerosis; (n = 47; YES (1,581,783 ± 145,154 a.u.), NO (1,179,192 ± 107,389 a.u.)). ( C ) The dependence of total AGEs fluorescence on the occurrence of macroangiopathy; (n = 58; YES (1,511,867 ± 619,228 a.u.), NO (1,105,011 ± 228,314 a.u.)). ( D ) The dependence of total soluble AGEs fluorescence on the occurrence of microangiopathy; (n = 47; YES (1,764,035 ± 207,484 a.u.), NO (1,205,829 ± 68,639 a.u.)). ( E ) The dependence of total soluble AGEs fluorescence on the occurrence of retinopathy; (n = 47; YES (2,749,771 ± 757,703 a.u.), NO (1,327,710 ± 66,108 a.u.)). ( F ) The dependence of soluble pentosidine fluorescence on the occurrence of retinopathy; (n = 47; YES (3,320,508 ± 527,192 a.u.), NO (3,069,839 ± 117,568 a.u.)). ( G ) The dependence of AGEs concentration determined in the competition ELISA test on the occurrence of ischemic stroke; (n = 39; YES (0.9252 ± 0.0687 mg/ml), NO (0.5244 ± 0.0517 mg/ml)). ( H ) The dependence of the concentration of sRAGE receptors on the occurrence of ischemic heart disease; (n = 49; YES (15,467 ± 3967 pg/ml), NO (7404 ± 1628 pg/ml)).

Journal: Scientific Reports

Article Title: Advanced glycation end products and their receptors in serum of patients with type 2 diabetes

doi: 10.1038/s41598-021-92630-0

Figure Lengend Snippet: Graphs of the dependence of AGEs fluorescence or content of sRAGE in the samples and occurrence diabetic complications in patients. The numbers given are the mean value of the results and the standard error of the mean (Mean ± SE). ( A ) The dependence of total AGEs fluorescence on the type of diabetes; (number of subjects = 49; Type 1 (1,167,393 ± 70,632 a.u.), Type 2 (1,517,352 ± 98,785 a.u.)). ( B ) The dependence of total soluble AGEs fluorescence on the occurrence of atherosclerosis; (n = 47; YES (1,581,783 ± 145,154 a.u.), NO (1,179,192 ± 107,389 a.u.)). ( C ) The dependence of total AGEs fluorescence on the occurrence of macroangiopathy; (n = 58; YES (1,511,867 ± 619,228 a.u.), NO (1,105,011 ± 228,314 a.u.)). ( D ) The dependence of total soluble AGEs fluorescence on the occurrence of microangiopathy; (n = 47; YES (1,764,035 ± 207,484 a.u.), NO (1,205,829 ± 68,639 a.u.)). ( E ) The dependence of total soluble AGEs fluorescence on the occurrence of retinopathy; (n = 47; YES (2,749,771 ± 757,703 a.u.), NO (1,327,710 ± 66,108 a.u.)). ( F ) The dependence of soluble pentosidine fluorescence on the occurrence of retinopathy; (n = 47; YES (3,320,508 ± 527,192 a.u.), NO (3,069,839 ± 117,568 a.u.)). ( G ) The dependence of AGEs concentration determined in the competition ELISA test on the occurrence of ischemic stroke; (n = 39; YES (0.9252 ± 0.0687 mg/ml), NO (0.5244 ± 0.0517 mg/ml)). ( H ) The dependence of the concentration of sRAGE receptors on the occurrence of ischemic heart disease; (n = 49; YES (15,467 ± 3967 pg/ml), NO (7404 ± 1628 pg/ml)).

Article Snippet: sRAGE was determined using the ELISA kit for the sRAGE human receptor (MyBioSource, cat. no. MBS766075) according to the manufacturer's instructions.

Techniques: Fluorescence, Concentration Assay, Enzyme-linked Immunosorbent Assay

The dependence of basic information about the health of patients on the concentration and fluorescence of AGEs and the concentration of AGE receptors. The statistically significant values are shown in red. PL—significance level for Levene’s test; PV – significance level for tke student’s t-test from the analysis of equality of variance; PNV – significance level for the students’s t-test of inequality of variance.

Journal: Scientific Reports

Article Title: Advanced glycation end products and their receptors in serum of patients with type 2 diabetes

doi: 10.1038/s41598-021-92630-0

Figure Lengend Snippet: The dependence of basic information about the health of patients on the concentration and fluorescence of AGEs and the concentration of AGE receptors. The statistically significant values are shown in red. PL—significance level for Levene’s test; PV – significance level for tke student’s t-test from the analysis of equality of variance; PNV – significance level for the students’s t-test of inequality of variance.

Article Snippet: sRAGE was determined using the ELISA kit for the sRAGE human receptor (MyBioSource, cat. no. MBS766075) according to the manufacturer's instructions.

Techniques: Concentration Assay, Fluorescence, Enzyme-linked Immunosorbent Assay, Indirect ELISA, Competitive ELISA